ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2026
A multi-state survival model to identify risk factors for lethal ovarian cancer.
Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundGiven primary prevention strategies for ovarian cancer, such as surgery and medications, have inherent risks, identifying those at high risk of lethal ovarian cancer is critical. We examined pre-diagnosis factors and risk of developing and dying from ovarian cancer among cancer-free women.
methodsAnalyses were conducted in three 12-year periods from 1980 to 2017 in the Nurses' Health Study (NHS) and NHSII cohorts. Potential risk factors were reproductive and hormonal variables, endometriosis history, smoking, low-dose aspirin, self-identified race, family history, depression, and adiposity over the life course. We used a multi-state survival model to estimate relative risks and 95% lower and upper confidence limits (RR, LCL-UCL) for lethal ovarian cancer among 211,420 cancer-free women, among whom 1,730 developed ovarian cancer and 660 died due to ovarian cancer in the same risk period as diagnosis.
resultsOf the 22 exposures evaluated, 10 were associated with lethal ovarian cancer. For example, nulliparity had an amplified association with lethal ovarian cancer (1.62, 1.23-2.13) due to associations with both incidence and mortality in the same direction. Oral contraceptive use ≥10 versus 0 years was associated with lethal ovarian cancer (0.65, 0.43-0.97) primarily due to association with incidence while ≥20 versus 0 pack-years of smoking was associated with lethal ovarian cancer (1.25, 1.02-1.53) primarily due to the mortality relationship.
conclusionsSeveral reproductive factors, depression, and self-identified race were associated with risk of lethal ovarian cancer. IMPACT: Evaluations of lethal ovarian cancer risk must consider differential associations of exposures with incidence and mortality.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.